Your browser doesn't support javascript.
loading
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier, Philippe A; Italiano, Antoine; Gomez-Roca, Carlos A; Le Tourneau, Christophe; Toulmonde, Maud; Cannarile, Michael A; Ries, Carola; Brillouet, Anne; Müller, Claudia; Jegg, Anna-Maria; Bröske, Ann-Marie; Dembowski, Markus; Bray-French, Katharine; Freilinger, Christine; Meneses-Lorente, Georgina; Baehner, Monika; Harding, Ross; Ratnayake, Jayantha; Abiraj, Keelara; Gass, Nathalie; Noh, Karen; Christen, Randolph D; Ukarma, Lidia; Bompas, Emmanuelle; Delord, Jean-Pierre; Blay, Jean-Yves; Rüttinger, Dominik.
Afiliación
  • Cassier PA; Department of Medicine, Centre Léon Bérard, Lyon, France.
  • Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr.
  • Gomez-Roca CA; Department of Medicine, Institut Claudius Regaud, Toulouse, France.
  • Le Tourneau C; Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.
  • Toulmonde M; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Cannarile MA; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Ries C; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Brillouet A; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Müller C; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Jegg AM; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Bröske AM; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Dembowski M; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Bray-French K; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Freilinger C; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Meneses-Lorente G; Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn, UK.
  • Baehner M; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Harding R; Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn, UK.
  • Ratnayake J; Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn, UK.
  • Abiraj K; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Gass N; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Noh K; Roche Innovation Center New York, Roche Pharmaceutical Research and Early Development, New York, NY, USA.
  • Christen RD; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Ukarma L; Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
  • Bompas E; Department of Medicine, Institut de Cancérologie de l'Ouest, Nantes, France.
  • Delord JP; Department of Medicine, Institut Claudius Regaud, Toulouse, France; Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.
  • Blay JY; Department of Medicine, Centre Léon Bérard, Lyon, France.
  • Rüttinger D; Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
Lancet Oncol ; 16(8): 949-56, 2015 Aug.
Article en En | MEDLINE | ID: mdl-26179200
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de los Tejidos Blandos / Sinovitis Pigmentada Vellonodular / Receptor de Factor Estimulante de Colonias de Macrófagos / Tumores de Células Gigantes / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de los Tejidos Blandos / Sinovitis Pigmentada Vellonodular / Receptor de Factor Estimulante de Colonias de Macrófagos / Tumores de Células Gigantes / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Francia